knowledge -WSS

knowledge

author：fashion 2025-08-23 10:41:12 - browse：1

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： It's been 20 years since Dolly the sheep. Where's my clone?

focus

WSS

Biotech stock slump in 2023: awaiting the turnaround

FDA panel to weigh approval of NurOwn, controversial ALS drug

Emergency workers more likely to restrain Black patients: study

Impact of Dobbs ruling felt at reproductive medicine meeting

Senate committee scrutinizes Medicare Advantage brokers

Medicare reduced heart disease by changing how it pays doctors

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Bright Health sells Medicare Advantage business to Molina

How AI helped researchers track recovery from depression

Tori Bowie and the unacceptable rates of Black maternal death

Biotech stock slump in 2023: awaiting the turnaround

Affirmative action in medical school literally saved lives

NIH confirmation hearing shows politicization of research

Sports medicine is finally prioritizing gender equality

Medical student insurance fails on mental health care coverage

Virginia high school admissions case could be legal follow

Researchers explore possible ties between long Covid, menopause

hotspot

Biotech lab space demand falls sharply

The explosion of genetic testing requires a new approach

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Readout LOUD podcast: possible new ALS drug, artificial wombs

Lawmakers consider Medicare pay reforms for doctors

Senate HELP committee spars over health care workforce policies

focus

hotspot

entertainment

leisure time